What's Happening?
Forma Life Sciences has announced its establishment as an independent contract development and manufacturing organization (CDMO) in the United States. This development follows the acquisition of BioDuro's US drug product development and manufacturing operations
by BioSelective Capital Investments. The company operates two cGMP-compliant facilities in Irvine, California, which support oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing. These facilities encompass 27 GMP manufacturing suites and have the capacity to produce over two billion tablet and capsule units annually. The leadership team includes Cyrus K. Mirsaidi as Executive Chairman and CEO, and Armand Amin as President, both of whom have extensive experience in the pharmaceutical industry.
Why It's Important?
The launch of Forma Life Sciences as a US-based CDMO is significant in the context of increasing focus on domestic pharmaceutical manufacturing and supply chain resilience. By providing a robust platform for drug development and manufacturing, Forma aims to support the pharmaceutical supply chain in the United States. This move aligns with broader industry trends emphasizing the importance of local manufacturing capabilities to ensure supply chain security and reduce dependency on international sources. The company's focus on oral solid dosage forms is particularly relevant given the high demand for these types of medications in the market.
